Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02000921 · ClinicalTrials.gov registry record · NA
Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
A NA study, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 136
- Enrollment target
NCT02000921: Completed NA study, sponsored by University of Minnesota.
NCT02000921 is a NA study that has completed, run by University of Minnesota. The registered enrollment target is 136 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02000921, a NA study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 136 participants
- Enrollment target
Study Summary
The main focus of this study is to determine the use of nicotine-containing products across the three experimental conditions. Subjects will be monitored to determine their continued use of assigned cigarettes, switching to other combusted and/or non-combusted tobacco, or cessation of all tobacco containing products.
Primary Outcome
The primary aim of the study is to determine the rate of use of alternative nicotine-containing products across the three experimental conditions.
Interventions
- OTHER VLNC cigarettes
- OTHER Combusted Products
- OTHER Non-combusted products
- OTHER CN cigarettes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-09 |
| Phase | NA |
What the finished NCT02000921 record still lists
NCT02000921 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 4 interventions - of which VLNC cigarettes is the first listed.
NCT02000921 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02000921 about?
NCT02000921 is a clinical study titled "Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors". The main focus of this study is to determine the use of nicotine-containing products across the three experimental conditions. Subjects will be monitored to determine their continued use of assigned cigarettes, switching to other combusted and/or non-combusted tobacco, or cessation of all tobacco co...
What is the current status of trial NCT02000921?
This trial is currently completed. It is a NA study. The enrollment target is 136 participants. The study started on 2013-12. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02000921?
The interventions under investigation include: VLNC cigarettes (OTHER), Combusted Products (OTHER), Non-combusted products (OTHER), CN cigarettes (OTHER).
Who is sponsoring clinical trial NCT02000921?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02000921's enrollment target sits among peer trials
136 722nd of 2000 higher than 1,275 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia